Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150867 | PMC |
| http://dx.doi.org/10.1097/CM9.0000000000002403 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer.
Chin Med J (Engl)
April 2023
Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.
Neoadjuvant ceritinib treatment in ALK-rearranged locally advanced adenosquamous carcinoma: A case report.
Thorac Cancer
August 2022
Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
Here, we first report a case of neoadjuvant ceritinib for locally advanced lung adenosquamous carcinoma. In this study, a locally advanced adenosquamous carcinoma (ASC) patient with EML4-ALK fusion who achieved a partial response with neoadjuvant ceritinib treatment after a cycle of neoadjuvant chemotherapy did not show significant efficacy. A complete surgical resection was performed with mild adhesions and a small amount of bleeding intraoperatively.
View Article and Find Full Text PDFPathological complete response to neoadjuvant ceritinib of a crizotinib-resistant, stage IIIB non-small cell lung cancer with ALK rearrangement: A case report.
Thorac Cancer
July 2021
Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
The treatment of stage IIIB non-small cell lung cancer (NSCLC) is complicated, the best strategy is chosen individually and surgery is usually not recommended. A 50-year-old female was diagnosed with locally advanced lung adenocarcinoma (stage IIIB, T2bN3M0). Fluorescence in situ hybridization (FISH) analysis revealed an ALK rearrangement.
View Article and Find Full Text PDFFirst-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lancet
March 2017
Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
Article Synopsis
- - The study evaluated the effectiveness and safety of ceritinib compared to standard platinum-based chemotherapy in patients with untreated ALK-rearranged non-small-cell lung cancer (NSCLC).
- - Conducted across 134 centers in 28 countries, the trial randomly assigned 376 patients to receive either ceritinib 750 mg/day or chemotherapy, assessing primary outcomes like progression-free survival.
- - Results showed that the ceritinib group had a median progression-free survival of 16.6 months compared to 8.1 months for the chemotherapy group, with common side effects including diarrhea, nausea, and vomiting.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!